Skip to main content
57th ASAM Annual Conference Main banner
Final Program


Preview Program
Feedback

Collaborative Session

Effectiveness of Extended-Release Buprenorphine in OUD: Results from NIDA CTN Studies
Developed in Collaboration with the National Institute on Drug Abuse

Friday, April 24, 2026
10:45 AM - 12:00 PM PT
Location: Gaslamp, Level 2
Presentations from two large, HEAL-funded, NIDA CTN multi-site trials: 1) The Medication Treatment for Opioid-dependent Expecting Mothers (MOMs) Trial showed that participants who received extended-release buprenorphine had significantly higher illicit opioid abstinence during pregnancy and was non-inferior postpartum. 2) The Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION) study showed successful implementation of extended release (XR)-BUP in ED patients with untreated OUD; and that it was superior to sublingual (SL) BUP in linkage to care post-ED induction.

Learning Objectives:

Learners will be able to:
  • Upon completion, the participant will be able to describe the role of extended-release buprenorphine in the management of pregnant and post-partum women with OUD
  • Upon completion the participant will be able to identify patients with OUD eligible for successful induction on extended-release buprenorphine when they present at ED settings
  • Upon completion the participant will be able to discuss the evidence for the safe and effective use of extended-release buprenorphine in two high risk populations
Disclosure(s):
Geetha A. Subramaniam, MD, DLFAPA, DFAACAP: No financial relationships to disclose
Michelle Lofwall, MD, MS, DFAPA, DFASAM: Braeburn Pharmaceuticals: Scientific advisor (Ongoing); Camurus: speaker/honorarium for non-speaker bureau scientific talk (Terminated, September 8, 2024)
Gail D'Onofrio, MD, MS, FACEM, FASAM: No financial relationships to disclose